Home Most Read
Most Read
  • Mengfei DONG, Tailin WANG, Jingyi ZHANG, Wenxia ZOU, Shu HAN, Xianglei LIU
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1023-1029. doi:10.16522/j.cnki.cjph.2026.09.001

    Human cytomegalovirus(HCMV) has an infection rate of over 90% in the general population. Although it mostly remains in an asymptomatic latent-infection state, it is the major pathogen responsible for congenital infection in newborns and fatal complications in immunocompromised patients. Currently, the prevention and treatment of HCMV infection face multiple challenges, including drug resistance, toxicity, and immune escape, highlighting the urgent need to integrate novel drugs and therapeutic strategies. The HCMV prevention and treatment strategies are evolving from single antiviral approaches toward multimodal synergistic directions. In the future, it will be necessary to combine structural biology, immune engineering, and clinical translational research to optimize comprehensive intervention systems. This review summarizes the research progress and future prospects of different types of drugs or strategies, including HCMV vaccines, anti-HCMV drugs, HCMV antibody drugs, and specific T-cell infusion therapy, with the aim of providing a reference for optimizing HCMV prevention and treatment strategies.

  • Qingtong MA, Zhenyu LIU, Jianxing NIU, Guanghao LIU, Yangsheng CHEN
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1054-1069. doi:10.16522/j.cnki.cjph.2026.09.005

    Based on the characteristics of molecular structure and synthetic process of falecalcitriol, together with a literature review, five related substances were identified, including process impurities, degradation impurities, and potential impurities. These were (1S,3R,14S,5Z,7E,23E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19),23-tetraene-1,3,25-triol(F2), (1S,3R,14S,5E,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol(F3), (1S,3R,14S,5E,6Z,8Z)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5(10),6,8(9)-triene-1,3,25-triol(F4), (1S,3R,14S,20S,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol(F5),and (1S,3R,14S,5Z,7E)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19),24-tetraene-1,3-diol(F6). By systematically analyzing the formation pathways and actual detected levels of these related substances, corresponding control strategies were established. Furthermore, related substances F2, F4, F5 and F6 were synthesized in this study,providing essential references for analytical method development and quality standard formulation.

  • Guizhou HAO, Hua ZHENG, Depeng LIU, Benguan YANG, Yunhui YAO, Zhong FENG
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1076-1082. doi:10.16522/j.cnki.cjph.2026.09.007

    The physicochemical properties and stability differences of semaglutide(1) bulk drug obtained from two different manufacturing processes were systematically evaluated using multi-scale characterization techniques. This study employed SEM, PXRD, TGA/DSC, dynamic vapor sorption analysis, and HPLC to characterize the microcrystal habit, polymorphic structure, thermal properties, hygroscopic behavior, and solubility of the samples, respectively.Influence factor tests were performed to preliminarily investigate their stability. The results showed that the samples prepared by both processes were amorphous and exhibited irregular flake-like crystal habits, with distinct differences in surface topography. Both samples displayed thermodynamic instability, susceptibility to thermal degradation, strong hygroscopicity, and low solubility in acidic media. Under accelerating conditions(high temperature, high humidity,and intense light exposure), the contents of related substances and moisture in both samples showed an increasing trend. In summary, 1bulk drug prepared by the two processes exhibited comparable quality, and both could be used for the development of 1injection and oral tablets. This study can provide data support and theoretical guidance for the screening of 1bulk drug and process selection during formulation development.

  • Xingyu WU, Jiahui WANG, Misi LI, Qingwei ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1049-1053. doi:10.16522/j.cnki.cjph.2026.09.004

    This study improved the synthesis process of the histone deacetylase inhibitor givinostat(1). Starting from 2,6-naphthalenedicarboxylic acid(2), 6-[(diethylamino)carbonyl]-2-naphthalenecarboxylic acid(3) was prepared via amide condensation with diethylamine. Compound 3was reduced with sodium borohydride/boron trifluoride etherate to obtain 6-[(diethylamino)methyl]-2-naphthalenemethanol(4), which was then converted into its hydrochloride salt in a solution of hydrogen chloride in ethyl acetate. Methyl 4-aminobenzoate(5) underwent a nucleophilic addition-elimination reaction with triphosgene to form an isocyanate intermediate, which then reacted with 4hydrochloride via nucleophilic addition to afford methyl 4-[[[[6-[(diethylamino)methyl]-2-naphthyl]methoxy]carbonyl]amino]benzoate(6). Hydrolysis of 6 with lithium hydroxide monohydrate afforded 4-[[[[6-[(diethylamino)methyl]-2-naphthyl]methoxy]carbonyl]-amino]benzoic acid(7). Compound 7 was subjected to an amide condensation reaction with O-(tetrahydropyran-2-yl)-hydroxylamine(O-THP) and was then hydrolyzed using hydrochloric acid, providing the target compound 1with an overall yield of 27.2%(based on 2) and an HPLC purity of 99.31%. The improved process features simple operation, high yield,mild conditions, and high product purity.

  • Yansuo YU, Shilin ZHAO, Baoming NING, Qiang LIU, Shuye QI
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1093-1098. doi:10.16522/j.cnki.cjph.2026.09.009

    To evaluate the feasibility of an imaging-based approach for determining the disintegration time of orally disintegrating tablets(ODTs), an imaging system integrating an industrial camera, illumination module, and image-processing workflow was developed. Using the Tricorptester as the reference instrument, the in vitro disintegration behaviors of three commercially available ODT formulations(containing ambroxol hydrochloride, domperidone, or loratadine,designated as formulation A to formulation C) were assessed, while the effects of imaging view on the measurement results and the applicability of the method to a special formulation were also investigated. The imaging approach continuously recorded the disintegration process and supported endpoint determination by quantifying residual projected area and mask-pixel changes. For formulations A and B, the imaging approach showed lower variability in the measurement results than the Tricorptester method. Disintegration time values measured from the two imaging views showed no statistically significant differences(P>0.05). For freeze-dried formulation C, for which the Tricorptester only recorded the disintegration time as “≥60 s” without identifying a definite endpoint, the imaging approach was still able to continuously record the disintegration process and identify a definite endpoint. These findings indicate that the imaging approach enables continuous recording and traceable endpoint determination of the disintegration process of ODTs, and provides complementary measurement capability for ultrathin formulations that are difficult to assess using mechanically triggered devices, thus serving as a useful complement to conventional disintegration testing methods.

  • Mengni FAN, Tingting ZHANG, Guohong QIN
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1030-1038. doi:10.16522/j.cnki.cjph.2026.09.002

    The drug-to-antibody ratio(DAR) is a critical quality attribute of antibody-drug conjugates(ADCs),directly affecting their efficacy, safety, and pharmacokinetic properties. This review systematically summarizes the analytical methods for DAR determination and optimization strategies for homogeneous ADCs. Current detection technologies include hydrophobic interaction chromatography, reversed-phase high-performance liquid chromatography, mass spectrometry,ultraviolet-visible spectroscopy, and emerging multi-dimensional liquid chromatography hyphenated techniques. In terms of homogeneity optimization, engineered site-specific conjugation approaches(e.g., THIOMAB, enzymatic conjugation)enable precise control of DAR. Hydrophilic modification of linkers and optimization of payload structure help improve drug loading while maintaining antibody stability. The optimal DAR should be determined by comprehensively considering target expression levels, tumor heterogeneity, and payload properties. This review provides references for ADC process development and quality control.

  • Haibing YIN, Wenjun FU, Jinfang ZHAO, Xiaonan LIU, Yongze WANG
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1121-1126. doi:10.16522/j.cnki.cjph.2026.09.014
  • Wenting OUYANG, Yanmei LI, Yuxia SUN, Shunnan ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1039-1048. doi:10.16522/j.cnki.cjph.2026.09.003

    Dry granulation is a green granulation process commonly used in the preparation of solid dosage forms of traditional Chinese medicine, and process scale-up is a critical step for realizing industrial production. Factors affecting granule quality include formulation factors, process parameters, and equipment factors. Among these, the physical properties of the material directly determine whether the material is suitable for dry granulation, while roller pressure is a critical process parameter influencing granule formation. However, current research on dry granulation process scale-up mainly relies on empirical experience and manual judgment, which can hardly meet the requirements of quality consistency in modern pharmaceutical development. According to whether the same series of equipment is used, this article summarizes two types of scale-up strategies: engineering-based similarity scale-up, and model-assisted scale-up based on process analytical technology or physics. Common problems encountered during scale-up are also analyzed in depth, and corresponding solutions are proposed, aiming to provide a reference for the scale-up of dry granulation processes.

  • Zhenping SHAO, Lingzhi LEI, Jing ZHANG, Jianguo YANG, Youfu WANG
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1070-1075. doi:10.16522/j.cnki.cjph.2026.09.006

    To support the quality control of budesonide, related substances B, C, J, and L specified in EP 11.0 were synthesized, namely 16α,17-[(1RS)-ethylidenebis(oxy)]-11β,21-dihydroxy-pregna-1,4-diene-3,20-dione(related substance B), 16α,17-[(1RS)-butylidenebis(oxy)]-11β-hydroxy-17-(hydroxymethyl)-D-homoandrosta-1,4-diene-3,17a-dione(related substance C), 16α,17-[(1RS)-butylidenebis(oxy)]-9α-bromo-11β,21-dihydroxy-pregna-1,4-diene-3,20-dione(related substance J) and 16α,17-[(1RS)-butylidenebis(oxy)]-21-hydroxy-pregna-1,4-diene-3,11,20-trione(related substance L). The synthetic methods for related substances B, C, and L had not been previously reported in the literature.The chemical structures of these related substances were confirmed by ¹H NMR, ¹³C NMR, and HRMS.

  • Zhongpeng WANG, Meng REN
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1137-1140. doi:10.16522/j.cnki.cjph.2026.09.017
News